In vitro effects of PPAR gamma ligands on gene expression in corpus luteum explants in non-pregnant pigs - Transcriptome analysis.
Corpus luteum
Estrous cycle
Late-luteal phase
Mid-luteal phase
Pig
Pioglitazone
Journal
Theriogenology
ISSN: 1879-3231
Titre abrégé: Theriogenology
Pays: United States
ID NLM: 0421510
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
16
12
2022
revised:
23
02
2023
accepted:
05
03
2023
medline:
12
4
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
The corpus luteum (CL) is a temporary endocrine structure in the female ovaries that develops cyclically in mature females during luteinization. This study aimed to determine the in vitro effects of peroxisome proliferator-activated receptor gamma (PPARγ) ligands on the transcriptomic profile of the porcine CL in the mid- and late-luteal phase of the estrous cycle using RNA-seq technology. The CL slices were incubated in the presence of PPARγ agonist - pioglitazone or antagonist - T0070907. We identified 40 differentially expressed genes after treatment with pioglitazone and 40 after treatment with T0070907 in the mid-luteal phase as well as 26 after pioglitazone and 29 after T0070907 treatment in the late-luteal phase of the estrous cycle. In addition, we detected differences in gene expression between the mid- and late-luteal phase without treatment (409 differentially expressed genes). This study revealed a number of novel candidate genes that may play a role in controlling the function of CL by regulating signaling pathways related to ovarian steroidogenesis, metabolic processes, cell differentiation, apoptosis, and immune responses. These findings become a basis for further studies to explain the mechanism of PPARγ action in the reproductive system.
Identifiants
pubmed: 36977370
pii: S0093-691X(23)00080-8
doi: 10.1016/j.theriogenology.2023.03.003
pii:
doi:
Substances chimiques
PPAR gamma
0
T 0070907
0
Pioglitazone
X4OV71U42S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-81Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors hereby confirm that neither the article nor any part of it has been published or is being considered for publication elsewhere. None of the authors has declared any conflict of interest that may arise from being named as an author on the manuscript.